CPE News (4/30/2019) – Biolux Research has closed a $14 million Series A round of financing led by Venrock with participation of Correlation Ventures, insiders and other investors. Biolux has also announced the appointment of David Thrower as Chief Executive Officer of the company.
Vancouver based Biolux manufactures OrthoPulse®, an FDA cleared orthodontic device currently being sold in the United States, Europe, and Asia. OrthoPulse is a non-invasive technology which, when used ten minutes each day, can accelerate orthodontic treatment by up to 50% and lead to better smiles with significantly less pain for both aligner and fixed appliance treatment modalities.
photo credit: Biolux
Biolux Research Raises $14M in Series A Round led by Venrock; Appoints David Thrower as Chief Executive Officer
April 30, 2019 11:00 AM Eastern Daylight Time
VANCOUVER, Canada–(BUSINESS WIRE)–Biolux Research announced the close of a $14M Series A round led by Venrock and joined by Correlation Ventures, insiders and other investors. Coincident with the completion of the round, Biolux announced that David Thrower has been appointed Chief Executive Officer of the company.
Biolux manufactures OrthoPulse®, an FDA cleared orthodontic device currently being sold in the United States, Europe, and Asia. OrthoPulse is a non-invasive technology which, when used ten minutes each day, can accelerate orthodontic treatment by up to 50% and lead to better smiles with significantly less pain for both aligner and fixed appliance treatment modalities.
Cami Samuels, Venrock Partner, stated, “The orthodontics industry is large, growing, and evolving – and we believe Biolux can be a vital part of that growth and transformation. Biolux has developed an innovative, evidence-based product that meaningfully transforms orthodontists’ practice economics and creates a fundamentally more satisfying consumer experience.”
Jay Chen, Biolux CFO, added, “This investment by a premier venture capitalist as well as the successful addition of an accomplished CEO to the Biolux team is an important validation of the OrthoPulse technology. We look forward to this exciting new chapter of Biolux’s growth.”
Over the last 25 years, David Thrower, Biolux CEO, has held executive leadership roles in a variety of medical device companies. The majority of his career has been spent driving growth in businesses that reside at the intersection of the consumer and medical devices spaces. David started his career at Bain & Company. More recently his roles have included VP of Global Marketing at Align Technology, CEO of InSound Medical, Asante Solutions and BAROnova, Inc. David earned a BS in Mathematical and Computational Sciences from Stanford University and an MBA from Harvard Business School.
“I am honored to be appointed as CEO of Biolux. It is a privilege to be part of a company that is revolutionizing orthodontic care. The proprietary Biolux technology creates significant value for the orthodontist and consumer alike,” said Thrower. “I am looking forward to leading the Biolux team in making OrthoPulse a part of the standard of orthodontic care around the globe by delivering better smiles in less time with more patient comfort.”
ABOUT BIOLUX RESEARCH
Biolux Research is a world leader in the development and commercialization of innovative Light Accelerated Orthodontic products. Biolux Research’s patented technologies have been developed to enhance clinical outcomes, increase patient comfort and dramatically reduce treatment time utilizing a safe, effective, and non-invasive approach. Biolux supports evidence-based innovation in orthodontics and has built a strong portfolio of clinical data supporting the efficacy of OrthoPulse. For more information visit www.orthopulse.com
Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock partners with entrepreneurs to build some of the world’s most disruptive, successful companies. With a primary focus on technology and healthcare, portfolio companies have included Apple, AveXis, Centocor, Dollar Shave Club, DoubleClick, Gilead, Idec Pharma, Illumina, Intel, Millennium, ShockWave, Nest, and Zeltiq. For more information, please visit Venrock’s website at www.venrock.com and follow the firm on Twitter at @venrock.